How to log a liraglutide titration and decide whether the daily-injection tradeoff makes sense for you.
At a glance
Liraglutide was the GLP-1 receptor agonist that proved the category could deliver meaningful weight loss before semaglutide and tirzepatide raised the ceiling. It is still in use, still approved (as Victoza for type 2 diabetes and Saxenda for weight management), and for some people the daily-injection cadence is actually preferable to the weekly competitors.
Liraglutide is a GLP-1 receptor agonist with a fatty acid side chain that extends its half-life to roughly 13 hours, enough to support once-daily dosing. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite.
Compared with semaglutide, the half-life is shorter, the average weight loss in trials is smaller, and the side-effect profile washes out faster after stopping. Those last two points are sometimes features rather than bugs.
Liraglutide is titrated. Saxenda protocols typically start at a low daily dose and increase weekly until reaching a maintenance dose, with the option to pause titration if side effects are intolerable. Injection is subcutaneous, rotating between abdomen, thigh, and upper arm. The titration schedule is on the prescribing information and should be followed with your clinician.
Average weight loss in liraglutide trials at maintenance dose runs noticeably below what semaglutide achieves, with significant variation across individuals. Some people respond well to liraglutide and not to weekly agents, or tolerate it better. The daily dosing means side effects do not accumulate the way they can with a long-half-life weekly drug, which is the main tradeoff worth thinking about.
Per injection: timestamp, dose, site. Per day: nausea, appetite, intake estimate, bowel movements, heart rate, hydration. Per week: weight, waist, average scores, side-effect days. Per quarter: HbA1c, lipids, CMP. Peptide IA handles daily-dose cadence cleanly and will flag missed doses, which is the most common quiet failure mode of a daily injectable.
Liraglutide is the slower, more controllable GLP-1. If a weekly agent overshot you on side effects or did not work, it is a legitimate alternative worth tracking properly rather than dismissing as obsolete.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.